Drilldown: Medicines
Use the filters below to narrow your results.
generic:
4-AcO-DET (1) ·
4-AcO-DiPT (1) ·
4-AcO-DMT (1) ·
4-AcO-MET (1) ·
4-AcO-MiPT (1) ·
4-HO-DET (1) ·
4-HO-DiPT (1) ·
4-HO-DPT (1) ·
4-HO-EPT (1) ·
4-HO-MET (1) ·
4-HO-MiPT (1) ·
5,6-MDO-DMT (1) ·
5-MeO-DALT (1) ·
5-MeO-DiPT (1) ·
5-MeO-DMT (1) ·
5-MeO-MiPT (1) ·
aMT (1) ·
Baeocystin (1) ·
Bufotenin (1) ·
DET (1) ·
Diltiazem (1) ·
DiPT (1) ·
DPT (1) ·
EPT (1) ·
MET (1) ·
MiPT (1) ·
Psilocin (1) ·
Verapamil (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1) ·
'"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)
uses:
None (26) ·
'"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' (1) ·
'"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' (1)
starting dose:
None (26) ·
ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) ·
IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1)
preparations:
fda max:
routes:
onset:
halflife:
bioavailability:
pregnancy:
None (26) ·
Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 28 results in range #1 to #28.